

**Ad hoc announcement according to § 17 MAR**

---

NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN USA,  
CANADA, JAPAN AND AUSTRALIA

**SYGNIS AG successfully completes Rights Offering  
and Private Placement**

- **Rights offering successfully completed and private placement oversubscribed**
- **Acquisition of Expedeon Holdings Ltd. secured**
- **Gross proceeds to cover additional cash payments to Expedeon shareholders and transaction-related expenses mainly**

**Madrid, Spain and Heidelberg, Germany, 14 July 2016** – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has successfully completed its rights offering and the subsequent private placement. Through these transactions, including the contribution in kind, the Company's share capital will increase by EUR 20,538,089.00 from EUR 16,803,891.00 to EUR 37,341,980.00 through the issue of 20,538,089 shares by way of a rights offering.

Existing shareholders subscribed a total number of 3,016,734 new shares. Further 1.801.466 shares were placed at a subscription price of EUR 1.10 per share with qualified investors in a subsequent rump placement, which resulted in gross proceeds of EUR 5.3 million. 15.719.889 remaining shares will be offered to Expedeon shareholders against contribution in kind.

Gross proceeds from the cash capital increase will be used for transaction-related expenses, including EUR 1.7 million cash payments to Expedeon shareholders, one-off integration costs and financing working capital.

\*\*\*\* End of ad hoc announcement \*\*\*\*

**For further information, please contact:**

**SYGNIS AG**

Pilar de la Huerta  
CEO/CFO  
Phone: +34 91 192 36 50  
Email: [pdelahuerta@sygnis.com](mailto:pdelahuerta@sygnis.com)

**MC Services AG**

Raimund Gabriel  
Managing Partner  
Phone: +49 89 210228 30  
Email: [raimund.gabriel@mc-services.eu](mailto:raimund.gabriel@mc-services.eu)

## **About SYGNIS AG: [www.sygnis.com](http://www.sygnis.com)**

SYGNIS, headquartered in Germany and Spain, specializes in the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast-growing fields of molecular biology and next-generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to a leading industry partner, for whole genome DNA amplification and sequencing, as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

### This document is not a securities prospectus and the information contained herein does not constitute an offer to sell or a solicitation of an offer to purchase any securities of SYGNIS AG in the Federal Republic of Germany nor under any other jurisdiction, in particular not where such kind of offer or solicitation is prohibited or lacks the required permission. Potential investors in securities of SYGNIS AG are asked to familiarize themselves with and to observe the respective restrictions.

A decision to invest in the securities of SYGNIS AG should only be made on the basis of the securities prospectus detailing the public offering of securities of SYGNIS AG in the Federal Republic of Germany, which, subject to the approval of the German Federal Financial Supervisory Authority (BaFin) is anticipated to be published under [www.sygnis.com/investors](http://www.sygnis.com/investors).

The information in this document may not be disseminated outside the Federal Republic of Germany in particular not in the United States, to U.S. Persons (as defined in regulation S of the U.S. Securities Act of 1933) or to publications with a general circulation in the United States with the exception of a such disclosures or announcements outside the Federal Republic of Germany which have to be made under the respective mandatory law. Any person who fails to comply with these restrictions may violate the security laws of certain jurisdictions, in particular of the United States. Securities in SYGNIS AG are not publicly offered outside the Federal Republic of Germany.

Some statements included in this ad hoc announcement, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###